Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Jashin J. Wu, Manish Patel, Feng Zeng, Ahong Huang, Xing Pan, Yiwen Cao, Naijun Chen, Huzefa Photowala, Vishvas Garg & Jeff Crowley. (2023) Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States. Journal of Dermatological Treatment 34:1.
Read now
Read now
Craig Leonardi, Rei Tao, Solmaz Setayeshgar, Sisi Wang, Russel Burge, Baojin Zhu & William N. Malatestinic. (2022) Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice. Journal of Dermatological Treatment 33:4, pages 2278-2284.
Read now
Read now
Mio Nakamura & John Koo. (2020) Safety considerations with combination therapies for psoriasis. Expert Opinion on Drug Safety 19:4, pages 489-498.
Read now
Read now
Ethan C. Levin, Rishu Gupta, Gabrielle Brown, Mona Malakouti & John Koo. (2014) Biologic fatigue in psoriasis. Journal of Dermatological Treatment 25:1, pages 78-82.
Read now
Read now
Articles from other publishers (25)
Astrid van Huizen, Paul Bank, Gayle van der Kraaij, Annelie Musters, Celine Busard, Stef Menting, Theo Rispens, Annick de Vries, Martijn van Doorn, Errol Prens, Jo Lambert, Juul van den Reek, Elke de Jong, Ron Mathôt & Phyllis Spuls. (2023) Quantifying The Effect Of Methotrexate On The Adalimumab Response In Psoriasis By Pharmacokinetic-Pharmacodynamic Modelling. Journal of Investigative Dermatology.
Crossref
Crossref
David Thein, Nana A.L. Rosenø, Julia-Tatjana Maul, Jashin J. Wu, Lone Skov, Lars Erik Bryld, Mads K. Rasmussen, Kawa Khaled Ajgeiy, Simon Francis Thomsen, Jacob P. Thyssen & Alexander Egeberg. (2023) Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment – a Nationwide Cohort Study. Journal of Investigative Dermatology 143:11, pages 2211-2218.e4.
Crossref
Crossref
Giovanni Damiani, Paolo Amerio, Federico Bardazzi, Carlo G. Carrera, Andrea Conti, Francesco Cusano, Paolo Dapavo, Clara DeSimone, May El Hachem, Gabriella Fabbrocini, Paolo Gisondi, Francesco Loconsole, Giuseppe Micali, Iria Neri, Aurora Parodi, Stefano Piaserico, Marco Romanelli, Luca Stingeni & Paolo D. M. Pigatto. (2023) Real-World Experience of Methotrexate in the Treatment of Skin Diseases: an Italian Delphi Consensus. Dermatology and Therapy 13:6, pages 1219-1241.
Crossref
Crossref
Astrid M. van Huizen, Gayle E. van der Kraaij, Celine I. Busard, Wouter Ouwerkerk, Juul M. P. A. van den Reek, Stef P. Menting, Errol P. Prens, Theo Rispens, Annick de Vries, Elke M. G. J. de Jong, Jo Lambert, Martijn B. A. van Doorn & Phyllis I. Spuls. (2023) Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three‐year follow‐up data of a single‐blind randomized controlled trial. Journal of the European Academy of Dermatology and Venereology.
Crossref
Crossref
Gayle van der Kraaij, Celine Busard, Juul van den Reek, Stef Menting, Annelie Musters, Barbara Hutten, Menno de Rie, Wouter Ouwerkerk, Sun-Jine van Bezooijen, Errol Prens, Theo Rispens, Annick de Vries, Elke de Jong, Wim de Kort, Jo Lambert, Martijn van Doorn & Phyllis Spuls. (2022) Adalimumab with Methotrexate vs. Adalimumab Monotherapy in Psoriasis: First-Year Results of a Single-Blind Randomized Controlled Trial. Journal of Investigative Dermatology 142:9, pages 2375-2383.e6.
Crossref
Crossref
Kourtney Pony & Mio Nakamura. 2022. Biologic Therapy for Psoriasis. Biologic Therapy for Psoriasis
53
63
.
Jochen H. O. Hoffmann, Christian Knoop, Kunt Schäkel, Alexander H. Enk & Eva N. Hadaschik. (2021) Long‐term safety of combination treatment with methotrexate and tumor necrosis factor (TNF)‐α antagonists versus TNF‐α antagonists alone in psoriatic patients. The Journal of Dermatology 48:6, pages 835-843.
Crossref
Crossref
Josef S. Smolen, Anthony Sebba, Eric M. Ruderman, Hendrik Schulze-Koops, Christophe Sapin, Amanda M. Gellett, Aubrey Trevelin Sprabery, Lingnan Li, Inmaculada de la Torre, Gaia Gallo, Soyi Liu-Leage, Sreekumar Pillai, Paulo Reis & Peter Nash. (2020) Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study. Rheumatology and Therapy 7:4, pages 1021-1035.
Crossref
Crossref
Mio Nakamura, Caleb Jeon & John Koo. 2018. Evidence-Based Psoriasis. Evidence-Based Psoriasis
113
128
.
C. I. Busard, S. P. Menting, J. S. van Bezooijen, J. M. van den Reek, B. A. Hutten, E. P. Prens, E. M. de Jong, M. B. van Doorn & P. I. Spuls. (2017) Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial. Trials 18:1.
Crossref
Crossref
Júlia Vide & Sofia Magina. (2017) Moderate to severe psoriasis treatment challenges through the era of biological drugs. Anais Brasileiros de Dermatologia 92:5, pages 668-674.
Crossref
Crossref
Dominika Wcisło-Dziadecka, Martyna Zbiciak-Nylec, Ligia Brzezińska-Wcisło & Urszula Mazurek. (2016) TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis. Postgraduate Medical Journal 92:1085, pages 172-178.
Crossref
Crossref
Anjali S. Vekaria & Mark G. Lebwohl. 2016. Therapy for Severe Psoriasis. Therapy for Severe Psoriasis
171
179
.
D. Thaçi, J. Humeniuk, Y. Frambach, R. Bissonnette, J.J. Goodman, S. Shevade, Y. Gong & C. Papavassilis. (2015) Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). British Journal of Dermatology 173:3, pages 777-787.
Crossref
Crossref
J.S. van Bezooijen, E.P. Prens, M.S. Pradeepti, R. Atiqi, M.W.J. Schreurs, B.C.P. Koch, T. van Gelder & M.B.A. van Doorn. (2015) Combining biologics with methotrexate in psoriasis: a systematic review. British Journal of Dermatology 172:6, pages 1676-1680.
Crossref
Crossref
F. Behrens, J. D. Canete, I. Olivieri, A. W. van Kuijk, N. McHugh & B. Combe. (2014) Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. Rheumatology 54:5, pages 915-926.
Crossref
Crossref
J.M. Carrascosa, I. Belinchón, P. de-la-Cueva, R. Izu, J. Luelmo & R. Ruiz-Villaverde. (2015) Expert Recommendations on Treating Psoriasis in Special Circumstances. Actas Dermo-Sifiliográficas (English Edition) 106:4, pages 292-309.
Crossref
Crossref
J.M. Carrascosa, I. Belinchón, P. de-la-Cueva, R. Izu, J. Luelmo & R. Ruiz-Villaverde. (2015) Recomendaciones de expertos para el tratamiento de la psoriasis en situaciones especiales. Actas Dermo-Sifiliográficas 106:4, pages 292-309.
Crossref
Crossref
Viraat Patel, Ethan Levin, Eric Sorenson, Mona Malakouti & John Y.M. Koo. (2018) Safety and Efficacy of Combining Biologic with Nonbiologic Therapies for Moderate to Severe Psoriasis: A Review. Psoriasis Forum 20a:4, pages 132-149.
Crossref
Crossref
Jennifer C. Cather & Jeffrey J. Crowley. (2014) Use of Biologic Agents in Combination with Other Therapies for the Treatment of Psoriasis. American Journal of Clinical Dermatology 15:6, pages 467-478.
Crossref
Crossref
Joaquín Borrás-Blasco, Luisa Obon, Isabel Hernández, Dolores-Elvira Casterá, Alejandro Gonzalez, F. Javier Abad & J. Dolores Rosique-Robles. (2014) Response to Ustekinumab in a Patient with Severe Psoriasis when Adalimumab Dose Escalation Fails. Journal of Pharmacy and Nutrition Sciences 4:2, pages 131-134.
Crossref
Crossref
L. Puig. (2014) Treatment of Moderate to Severe Plaque Psoriasis With Biologics: Analysis of the Additional Cost of Temporary Dose Escalation vs Switch to Another Biologic After Failure of Maintenance Therapy. Actas Dermo-Sifiliográficas (English Edition) 105:4, pages 401-412.
Crossref
Crossref
L. Puig. (2014) Tratamiento de la psoriasis en placas moderada a grave con fármacos biológicos: análisis del sobrecoste de la intensificación temporal frente a cambio a otro biológico en caso de fracaso secundario. Actas Dermo-Sifiliográficas 105:4, pages 401-412.
Crossref
Crossref
L. Puig, J.M. Carrascosa, G. Carretero, P. de la Cueva, R.F. Lafuente-Urrez, I. Belinchón, M. Sánchez-Regaña, M. García-Bustínduy, M. Ribera, M. Alsina, C. Ferrándiz, E. Fonseca, V. García-Patos, E. Herrera, J.L. López-Estebaranz, S.E. Marrón, J.C. Moreno, J. Notario, R. Rivera, C. Rodriguez-Cerdeira, A. Romero, R. Ruiz-Villaverde, R. Taberner & D. Vidal. (2013) Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment. Actas Dermo-Sifiliográficas (English Edition) 104:8, pages 694-709.
Crossref
Crossref
L. Puig, J.M. Carrascosa, G. Carretero, P. de la Cueva, R.F. Lafuente-Urrez, I. Belinchón, M. Sánchez-Regaña, M. García-Bustínduy, M. Ribera, M. Alsina, C. Ferrándiz, E. Fonseca, V. García-Patos, E. Herrera, J.L. López Estebaranz, S.E. Marrón, J.C. Moreno, J. Notario, R. Rivera, C. Rodriguez-Cerdeira, A. Romero, R. Ruiz-Villaverde, R. Taberner & D. Vidal. (2013) Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I. Consideraciones de eficacia y selección del tratamiento. Actas Dermo-Sifiliográficas 104:8, pages 694-709.
Crossref
Crossref